A subset of osteoblasts expressing high endogenous levels of pparγ switches fate to adipocytes in the rat calvaria cell culture model

PLoS ONE

Volumn 5, Issue 7, 2010, Pages

  Yoshiko, Yuji ^a   Oizumi, Kiyoshi ^b   Hasegawa, Takuro ^a   Minamizaki, Tomoko ^a   Tanne, Kazuo ^a   Maeda, Norihiko ^a   Aubin, Jane E ^c  

^a HIROSHIMA UNIVERSITY   (Japan)

^b DAIICHI SANKYO CO   (Japan)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; COMPLEMENTARY RNA; MESSENGER RNA; MYOD PROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; ROSIGLITAZONE; TRANSCRIPTION FACTOR RUNX2; TRANSCRIPTION FACTOR SOX9;

ADIPOCYTE; ANIMAL CELL; ANIMAL CELL CULTURE; ARTICLE; CALVARIA; CELL FATE; CELL LABELING; CELL LINEAGE; CELL MATURATION; CELL NUCLEUS; CELL SUBPOPULATION; COLONY FORMING UNIT; CONTROLLED STUDY; CYTOPLASM; FETUS; GENE EXPRESSION REGULATION; NONHUMAN; OSTEOBLAST; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN TRANSPORT; QUANTITATIVE STUDY; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION; ANIMAL; CELL CULTURE; CYTOLOGY; FLUORESCENCE MICROSCOPY; IMMUNOHISTOCHEMISTRY; METABOLISM; SKULL; WESTERN BLOTTING; WISTAR RAT;

RATTUS;

ADIPOCYTES; ANIMALS; BLOTTING, WESTERN; CELLS, CULTURED; IMMUNOHISTOCHEMISTRY; MICROSCOPY, FLUORESCENCE; OSTEOBLASTS; PPAR GAMMA; RATS; RATS, WISTAR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SKULL;

EID: 77955606279     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0011782     Document Type: Article

References (51)

1. Akune T, Ohba S, Kamekura S, Yamaguchi M, Chung UI, et al. (2004) PPARΓ insufficiency enhances osteogenesis through osteoblast formation from bone marrow progenitors. J Clin Invest 113: 846-855.
2. Akiyama H, Chaboissier MC, Martin JF, Schedl A, de Crombrugghe B (2002) The transcription factor Sox9 has essential roles in successive steps of the chondrocyte differentiation pathway and is required for expression of Sox5 and Sox6. Genes Dev 16: 2813-2828.
3. Tapscott SJ (2005) The circuitry of a master switch: MyoD and the regulation of skeletal muscle gene transcription. Development 132: 2685-2695.
4. Meunier P, Aaron J, Edouard C, Vignon G (1971) Osteoporosis and the replacement of cell populations of the marrow by adipose tissue. A quantitative study of 84 iliac bone biopsies. Clin Orthop Relat Res 80: 147-154.
5. Justesen J, Stenderup K, Ebbesen EN, Mosekilde L, Steiniche T, et al. (2001) Adipocyte tissue volume in bone marrow is increased with aging and in patients with osteoporosis. Biogerontology 2: 165-171.
6. Nuttall ME, Patton AJ, Olivera DL, Nadeau DP, Gowen M (1998) Human trabecular bone cells are able to express both osteoblastic and adipocytic phenotype: implications for osteopenic disorders. J Bone Miner Res 13:371-382.
7. Kodama Y, Takeuchi Y, Suzawa M, Fukumoto S, Murayama H, et al. (1998) Reduced expression of interleukin-11 in bone marrow stromal cells of senescence-accelerated mice (SAMP6): relationship to osteopenia with enhanced adipogenesis. J Bone Miner Res 13: 1370-1377.
8. Ali AA, Weinstein RS, Stewart SA, Parfitt AM, Manolagas SC, et al. (2005) Rosiglitazone causes bone loss in mice by suppressing osteoblast differentiation and bone formation. Endocrinology 146: 1226-1235.
9. Lecka-Czernik B, Moerman EJ, Grant DF, Lehmann JM, Manolagas SC, et al. (2002) Divergent effects ofselective peroxisome proliferator-activated receptor-Γ 2 ligands on adipocyte versus osteoblast differentiation. Endocrinology 143:2376-2384.
10. Johnson TE, Vogel R, Rutledge SJ, Rodan G, Schmidt A (1999) Thiazolidi-nedione effects on glucocorticoid receptor-mediated gene transcription and differentiation in osteoblastic cells. Endocrinology 140: 3245-3254.
11. Rzonca SO, Suva LJ, Gaddy D, Montague DC, Lecka-Czernik B (2004) Bone is a target for the antidiabetic compound rosiglitazone. Endocrinology 145:401-406.
12. Ziouzenkova O, Orasanu G, Sukhova G, Lau E, Berger JP, et al. (2007) Asymmetric cleavage of β-carotene yields a transcriptional repressor ofretinoid X receptor and peroxisome proliferator-activated receptor responses. Mol Endocrinol 21: 77-88.
13. Zandbergen F, Mandard S, Escher P, Tan NS, Patsouris D, et al. (2005) The G0/G1 switch gene 2 is a novel PPAR target gene. Biochem J 392: 313-324.
14. Rosen ED, Walkey CJ, Puigserver P, Spiegelman BM (2000) Transcriptional regulation of adipogenesis. Genes Dev 14: 1293-1307.
15. Ferre P (2004) The biology of peroxisome proliferator-activated receptors: relationship with lipid metabolism and insulin sensitivity. Diabetes 53 Suppl 1:S43-50.
16. Lecka-Czernik B, Gubrij I, Moerman EJ, Kajkenova O, Lipschitz DA, et al. (1999) Inhibition of Osf2/Cbfa1 expression and terminal osteoblast differentiation by PPARΓ2. J Cell Biochem 74: 357-371.
17. Garcia T, Roman-Roman S, Jackson A, Theilhaber J, Connolly T, et al. (2002) Behavior of osteoblast, adipocyte, and myoblast markers in genome-wide expression analysis of mouse calvaria primary osteoblasts in vitro. Bone 31:205-211.
18. Hasegawa T, Oizumi K, Yoshiko Y, Tanne K, Maeda N, et al. (2008) The PPARΓ-selective ligand BRL-49653 differentially regulates the fate choices of rat calvaria versus rat bone marrow stromal cell populations. BMC Dev Biol 8: 71.
19. Aubin JE (2001) Regulation of osteoblast formation and function. Rev Endocr Metab Disord 2: 81-94.
20. Candeliere GA, Liu F, Aubin JE (2001) Individual osteoblasts in the developing calvaria express different gene repertoires. Bone 28: 351-361.
21. Calvi LM, Sims NA, Hunzelman JL, Knight MC, Giovannetti A, et al. (2001) Activated parathyroid hormone/parathyroid hormone-related protein receptor in osteoblastic cells differentially affects cortical and trabecular bone. J Clin Invest 107: 277-286.
22. Zhang S, Uchida S, Inoue T, Chan M, Mockler E, et al. (2006) Side population (SP) cells isolated from fetal rat calvaria are enriched for bone, cartilage, adipose tissue and neural progenitors. Bone 38: 662-670.
23. Turksen K, Aubin JE (1991) Positive and negative immunoselection for enrichment of two classes of osteoprogenitor cells. J Cell Biol 114: 373-384.
24. Bellows CG, Heersche JN (2001) The frequency of common progenitors for adipocytes and osteoblasts and of committed and restricted adipocyte and osteoblast progenitors in fetal rat calvaria cell populations. J Bone Miner Res 16:1983-1993.
25. Liu F, Malaval L, Aubin JE (2003) Global amplification polymerase chain reaction reveals novel transitional stages during osteoprogenitor differentiation. J Cell Sci 116: 1787-1796.
26. Diascro DD Jr, Vogel RL, Johnson TE, Witherup KM, Pitzenberger SM, et al. (1998) High fatty acid content in rabbit serum is responsible for the differentiation of osteoblasts into adipocyte-like cells. J Bone Miner Res 13: 96-106.
27. Park CW, Zhang Y, Zhang X, Wu J, Chen L, et al. (2006) PPARα agonist fenofibrate improves diabetic nephropathy in db/db mice. Kidney Int 69: 1511-1517.
28. Jeon MJ, Kim JA, Kwon SH, Kim SW, Park KS, et al. (2003) Activation of peroxisome proliferator-activated receptor-Γ inhibits the Runx2-mediated transcription of osteocalcin in osteoblasts. JBiol Chem 278: 23270-23277.
29. Kobayashi H, Gao Y, Ueta C, Yamaguchi A, Komori T (2000) Multilineage differentiation of Cbfa1-deficient calvarial cells in vitro. Biochem Biophys Res Commun 273: 630-636.
30. Kim SW, Her SJ, Kim SY, Shin CS (2005) Ectopic overexpression of adipogenic transcription factors induces transdifferentiation of MC3T3-E1 osteoblasts. Biochem Biophys Res Commun 327: 811-819.
31. Malaval L, Liu F, Roche P, Aubin JE (1999) Kinetics of osteoprogenitor proliferation and osteoblast differentiation in vitro. JCell Biochem 74: 616-627.
32. Jackson SM, Demer LL (2000) Peroxisome proliferator-activated receptor activators modulate the osteoblastic maturation of MC3T3-E1 preosteoblasts. FEBS Lett 471: 119-124.
33. Hummasti S, Tontonoz P (2006) The peroxisome proliferator-activated receptor N-terminal domain controls isotype-selective gene expression and adipogenesis. Mol Endocrinol 20: 1261-1275.
34. Tornvig L, Mosekilde LI, Justesen J, Falk E, Kassem M (2001) Troglitazone treatment increases bone marrow adipose tissue volume but does not affect trabecular bone volume in mice. Calcif Tissue Int 69: 46-50.
35. Lazarenko OP, Rzonca SO, Suva LJ, Lecka-Czernik B (2006) Netoglitazone is a PPAR-Γ ligand with selective effects on bone and fat. Bone 38: 74-84.
36. Hu E, Tontonoz P, Spiegelman BM (1995) Transdifferentiation of myoblasts by the adipogenic transcription factors PPARΓ and C/EBPα. Proc Natl Acad Sci U S A 92: 9856-9860.
37. Fux C, Mitta B, Kramer BP, Fussenegger M (2004) Dual-regulated expression of C/EBP-a and BMP-2 enables differential differentiation of C2C12 cells into adipocytes and osteoblasts. Nucleic Acids Res 32: e1.
38. Gutierrez S, Javed A, Tennant DK, van Rees M, Montecino M, et al. (2002) CCAAT/enhancer-binding proteins (C/EBP)β and δ activate osteocalcin gene transcription and synergize with Runx2 at the C/EBP element to regulate bone-specific expression. J Biol Chem 277: 1316-1323.
39. Gurnell M (2005) Peroxisome proliferator-activated receptor Γ and the regulation of adipocyte function: lessons from human genetic studies. Best Pract Res Clin Endocrinol Metab 19: 501-523.
40. Khan E, Abu-Amer Y (2003) Activation of peroxisome proliferator-activated receptor-Γ inhibits differentiation of preosteoblasts. J Lab Clin Med 142: 29-34.
41. Zhou G, Zheng Q, Engin F, Munivez E, Chen Y, et al. (2006) Dominance of SOX9 function over RUNX2 during skeletogenesis. Proc Natl Acad Sci U S A 103: 19004-19009.
42. Mueller E, Drori S, Aiyer A, Yie J, Sarraf P, et al. (2002) Genetic analysis of adipogenesis through peroxisome proliferator-activated receptor Γ isoforms. J Biol Chem 277: 41925-41930.
43. Maurin AC, Chavassieux PM, Meunier PJ (2005) Expression of PPARΓ and β/δ in human primary osteoblastic cells: influence of polyunsaturated fatty acids. Calcif Tissue Int 76: 385-392.
44. Bruedigam C, Koedam M, Chiba H, Eijken M, van Leeuwen JP (2008) Evidence for multiple peroxisome proliferator-activated receptor Γ transcripts in bone: fine-tuning by hormonal regulation and mRNA stability. FEBS Lett 582:1618-1624.
45. Shockley KR, Lazarenko OP, Czernik PJ, Rosen CJ, Churchill GA, et al. (2009) PPARΓ2 nuclear receptor controls multiple regulatory pathways of osteoblast differentiation from marrow mesenchymal stem cells. J Cell Biochem 106:232-246.
46. Bellows CG, Aubin JE, Heersche JN, Antosz ME (1986) Mineralized bone nodules formed in vitro from enzymatically released rat calvaria cell populations. Calcif Tissue Int 38: 143-154.
47. Yoshiko Y, Maeda N, Aubin JE (2003) Stanniocalcin 1 stimulates osteoblast differentiation in rat calvaria cell cultures. Endocrinology 144: 4134-4143.
48. Backesjo CM, Li Y, Lindgren U, Haldosen LA (2006) Activation of Sirt1 decreases adipocyte formation during osteoblast differentiation of mesenchymal stem cells. JBone Miner Res 21: 993-1002.
49. Sloop KW, Surface PL, Heiman ML, Slieker LJ (1998) Changes in leptin expression are not associated with corresponding changes in CCAAT/enhancer binding protein-α. Biochem Biophys Res Commun 251: 142-147.
50. Umayahara Y, Ji C, Centrella M, Rotwein P, McCarthy TL (1997) CCAAT/enhancer-binding protein 8 activates insulin-like growth factor-I gene transcription in osteoblasts. Identification of a novel cyclic AMP signaling pathway in bone. J Biol Chem 272: 31793-31800.
51. Aoyagi K, Tatsuta T, Nishigaki M, Akimoto S, Tanabe C, et al. (2003) A faithful method for PCR-mediated global mRNA amplification and its integration into microarray analysis on laser-captured cells. Biochem Biophys Res Commun 300:915-920.